27 August 2021 - Genentech today announced that the company has made the decision to voluntarily withdraw the U.S. accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple negative breast cancer whose tumours express PD-L1, as determined by a U.S. FDA-approved test. 

Genentech made this decision following consultation with the FDA based on the agency’s assessment of the current metastatic triple negative breast cancer treatment landscape and in accordance with the requirements of the accelerated approval program.

Read Genentech press release